Navigation Links
Chronix Biomedical's serum DNA assays monitor disease activity and treatment response in MS
Date:4/5/2010

San Jose, California, April 6, 2010 Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis (MS). Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells. A growing body of publications from Chronix and other researchers shows that this circulating DNA can be identified and analyzed to provide a diagnostic window into ongoing changes in the genome associated with specific diseaseschanges that can be used to track the presence or absence of active disease. This new study is the first to show that the Chronix approach can be used to monitor the clinical status of a chronic disease. The findings are published in the current online edition of the Journal of Molecular Diagnostics.*

"These positive data further validate the premise underlying the Chronix approach, showing that the many genetic anomalies associated with active and stable relapsing-remitting MS can be detected by analyzing DNA fragments circulating in the blood serum," said Mario Clerici, M.D., Chair of Immunology, Department of Biomedical Sciences and Technologies, University of Milano, Milan, Italy and a co-author of the study. "The prognostic value achieved in this study supports the ability of this new approach to help manage relapsing-remitting multiple sclerosis, potentially offering clinicians a new tool to easily assess which MS treatment options are most effective for their patients, as well as providing critical information that will facilitate development of the next generation of MS therapeutics."

In the study, researchers applied advanced analytical techniques developed by Chronix to identify genomic DNA fingerprints in the bloodstream of 28 MS patients known to have r
'/>"/>

Contact: Barbara Lindheim
blindheim@biocompartners.com
917-355-9234
BioCom Partners
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Study shows Chronix technology using serum DNA can identify early presence of disease
2. NIST issues human milk and blood serum SRMs for contaminant measurements
3. Syracuse University partners with Serum Institute of India to develop vaccines for children
4. NIH grants Phylonix Phase II SBIR to develop high-throughput in vivo zebrafish assays
5. Genetic Engineering & Biotechnology News reports on growing use of cell-based assays
6. Chemist monitors nanotechnologys environmental impact
7. Counting frogs: Why monitoring our amphibian populations is important
8. Boost ivory trade monitoring and enforcement before allowing one-off sales: UBC researcher
9. Fluorescence monitoring and effect of photodynamic therapy for port wine stains
10. Volcano monitoring will target hazard threat to Marianas, US military and commercial jets
11. ACS webinar features developments in online water and wastewater monitoring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2015)... 2015 Fingerprint Cards (FPC) has received ... FPC1155 and FPC1035 from one if its module partners. Deliveries ... Q3 2015 and the sensors will be used by smartphone ... for 2015 hereby amount to 740 MSEK to date. In ... MSEK and a number of smaller orders not separately communicated ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
(Date:5/8/2015)... Calif. , May 8, 2015 Synaptics Inc. ... solutions, today announced that members of the executive management team ... Morgan 43rd Annual Technology, Media and Telecom Conference Date: ... Hotel in Boston, MA ... 27, 2015 Time: 2:45pm ET Location: The New York Palace ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2
... consume foods purchased in vending machines are more likely to ... with being overweight, obese or at risk for chronic health ... research from the University of Michigan Medical School. The ... bars and other related sales that compete with USDA lunch ...
... PASADENA, Calif.Researchers at the California Institute of Technology ... carbon just one atom thickto visualize the structure of ... first direct images of how water coats surfaces at ... potentially unlimited number of other molecules, including antibodies and ...
... A new study from the Center for Interdisciplinary Chronobiological ... additional link between Light At Night (LAN) and cancer. ... out at the University of Haifa that also established ... ,environmental light pollution, which the study has shown is ...
Cached Biology News:Children who eat vended snack foods face chronic health problems, poor diet 2Caltech chemists develop simple technique to visualize atomic-scale structures 2Caltech chemists develop simple technique to visualize atomic-scale structures 3Connection between light at night and cancer revealed in additional study 2
(Date:5/28/2015)... May 28, 2015 In two different ... L. Sherley, M.D., Ph.D., will present the company’s unique ... In a conference talk, he will describe Asymmetrex ... designs with computer simulation to produce the first-ever technology ... and quality over time in culture. When leading ...
(Date:5/27/2015)... DUBLIN , May 26, 2015 ... addition of the "Global Breast Cancer Monoclonal ... offering. Globally, Roche seems to dominate ... largest inventory. Its block buster molecule, Herceptin has ... years. It was found that breast cancer cells ...
(Date:5/27/2015)... The ALS Therapy Development Institute ... owned subsidiary, Anelixis Therapeutics , $1.5 million toward ... targets the innate immune system. The funding comes from ... from the 2014 social media phenomenon known as the ... million raised directly by the Institute through last year’s ...
(Date:5/27/2015)... THOUSAND OAKS, Calif. , May 27, 2015 /PRNewswire/ ... company, has been awarded a U.S. patent for a ... gene in areas such as research, product development and ... useful in regulating key biosynthetic processes that are the ... to offer other seed companies a commercial license to ...
Breaking Biology Technology:Asymmetrex Will Discuss the Importance of Adult Tissue Stem Cell Time with 3D Tissue Engineers at the 14th Annual World Preclinical Congress in Boston in June 2Asymmetrex Will Discuss the Importance of Adult Tissue Stem Cell Time with 3D Tissue Engineers at the 14th Annual World Preclinical Congress in Boston in June 3Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Ice Bucket Challenge Advances Antibody Toward Clinical Trial for ALS 2Ice Bucket Challenge Advances Antibody Toward Clinical Trial for ALS 3Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3
... 28 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... (NASDAQ: ATHX) announced positive results from its phase ... therapy product, administered to individuals following acute myocardial ... heart attack. The study results, which represent at ...
... CLEVELAND, Ohio , ... leading provider of medical education and simulation training,products for ... the company,s continued global expansion. Simbionix has increased,the size ... of its Corporate,Headquarters in Cleveland, OH , and ...
... Researchers have discovered mechanisms critical to interactions between hot ... fusion reactor, part of work aimed at developing coatings ... Fusion powers the stars and could lead to ... plant would produce 10 times more energy than a ...
Cached Biology Technology:Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 2Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 3Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 4Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 5Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 6Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 7Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 8Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 9Simbionix Continues its Global Expansion 2Findings show promise for nuclear fusion test reactors 2Findings show promise for nuclear fusion test reactors 3